Zilico Limited Company

Zilico is focused on developing next generation cancer diagnostics to provide real-time diagnosis for cervical cancer. Zilico's flagship product, ZedScan is a diagnostic for cervical cancer. It is in routine use across several hospitals in the NHS.
Industry: Pelvic & Uterine Healthcare
Headquarters: Manchester, Manchester, United Kingdom
Founded Date: 06-02-2006
Employees Number: 11-50
Investors Number: 8
Total Funding: $23,546,581
Estimated Revenue: $1M to $10M
Last Funding Date: 2018-02-04
Last Funding Type: Corporate Round

Visit Website
Register and Claim Ownership